

Greg Matlashewski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6688544/publications.pdf>

Version: 2024-02-01

109
papers

6,801
citations

81900

39
h-index

64796

79
g-index

118
all docs

118
docs citations

118
times ranked

6003
citing authors

#	ARTICLE	IF	CITATIONS
1	An intraspecies <i>Leishmania donovani</i> hybrid from the Indian subcontinent is associated with an atypical phenotype of cutaneous disease. <i>IScience</i> , 2022, 25, 103802.	4.1	12
2	Specificity of SARS-CoV-2 Antibody Detection Assays against S and N Proteins among Pre-COVID-19 Sera from Patients with Protozoan and Helminth Parasitic Infections. <i>Journal of Clinical Microbiology</i> , 2022, 60, JCM0171721.	3.9	7
3	<i>Leishmania</i> Major Centrin Gene-Deleted Parasites Generate Skin Resident Memory T-Cell Immune Response Analogous to Leishmanization. <i>Frontiers in Immunology</i> , 2022, 13, 864031.	4.8	7
4	Centrin-deficient <i>Leishmania mexicana</i> confers protection against New World cutaneous leishmaniasis. <i>Npj Vaccines</i> , 2022, 7, 32.	6.0	19
5	Reconstitution of <i>Mycobacterium marinum</i> Nonhomologous DNA End Joining Pathway in <i>Leishmania</i> . <i>MSphere</i> , 2022, 7, .	2.9	4
6	Response to Visceral Leishmaniasis Cases through Active Case Detection and Vector Control in Low-Endemic Hilly Districts of Nepal. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 107, 349-354.	1.4	2
7	Seropositivity of Visceral leishmaniasis on people of VL endemic three districts of Nepal. <i>Parasitology International</i> , 2021, 80, 102236.	1.3	2
8	Evidence that a naturally occurring single nucleotide polymorphism in the RagC gene of <i>Leishmania donovani</i> contributes to reduced virulence. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009079.	3.0	11
9	Revival of Leishmanization and Leishmanin. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 639801.	3.9	22
10	<i>Leishmania donovani</i> hybridisation and introgression in nature: a comparative genomic investigation. <i>Lancet Microbe</i> , The, 2021, 2, e250-e258.	7.3	26
11	A review of the leishmanin skin test: A neglected test for a neglected disease. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009531.	3.0	22
12	Preclinical validation of a live attenuated dermatropic <i>Leishmania</i> vaccine against vector transmitted fatal visceral leishmaniasis. <i>Communications Biology</i> , 2021, 4, 929.	4.4	30
13	Characterization of a new <i>Leishmania</i> major strain for use in a controlled human infection model. <i>Nature Communications</i> , 2021, 12, 215.	12.8	28
14	The Phosphoenolpyruvate Carboxykinase Is a Key Metabolic Enzyme and Critical Virulence Factor of <i>Leishmania major</i> . <i>Journal of Immunology</i> , 2021, 206, 1013-1026.	0.8	3
15	Comparison of Novel Sandfly Control Interventions: A Pilot Study in Bangladesh. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 1786-1794.	1.4	3
16	A second generation leishmanization vaccine with a markerless attenuated <i>Leishmania</i> major strain using CRISPR gene editing. <i>Nature Communications</i> , 2020, 11, 3461.	12.8	72
17	Sensing Host Arginine Is Essential for <i>Leishmania</i> Parasites' Intracellular Development. <i>MBio</i> , 2020, 11, .	4.1	17
18	Application of CRISPR/Cas9-Mediated Genome Editing in <i>Leishmania</i> . <i>Methods in Molecular Biology</i> , 2020, 2116, 199-224.	0.9	18

#	ARTICLE	IF	CITATIONS
19	Relationship of Serum Antileishmanial Antibody With Development of Visceral Leishmaniasis, Post-kala-azar Dermal Leishmaniasis and Visceral Leishmaniasis Relapse. <i>Frontiers in Microbiology</i> , 2019, 10, 2268.	3.5	10
20	Single-Strand Annealing Plays a Major Role in Double-Strand DNA Break Repair following CRISPR-Cas9 Cleavage in <i>Leishmania</i> . <i>MSphere</i> , 2019, 4, .	2.9	34
21	Barriers of Visceral Leishmaniasis reporting and surveillance in Nepal: comparison of governmental <sc>VL</sc> program districts with non program districts. <i>Tropical Medicine and International Health</i> , 2019, 24, 192-204.	2.3	9
22	Intervention Packages for Early Visceral Leishmaniasis Case Detection and Sandfly Control in Bangladesh: A Comparative Analysis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 97-107.	1.4	7
23	Integrating Case Detection of Visceral Leishmaniasis and Other Febrile Illness with Vector Control in the Post-Elimination Phase in Nepal. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 108-114.	1.4	19
24	A complete <i>Leishmania donovani</i> reference genome identifies novel genetic variations associated with virulence. <i>Scientific Reports</i> , 2018, 8, 16549.	3.3	41
25	Atypical leishmaniasis: A global perspective with emphasis on the Indian subcontinent. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006659.	3.0	74
26	Development of a sandwich ELISA to detect <i>Leishmania</i> 40S ribosomal protein S12 antigen from blood samples of visceral leishmaniasis patients. <i>BMC Infectious Diseases</i> , 2018, 18, 500.	2.9	16
27	Evaluation of Real-time PCR for Diagnosis of Post-Kala-azar Dermal Leishmaniasis in Endemic Foci of Bangladesh. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy234.	0.9	16
28	Optimized CRISPR-Cas9 Genome Editing for <i>Leishmania</i> and Its Use To Target a Multigene Family, Induce Chromosomal Translocation, and Study DNA Break Repair Mechanisms. <i>MSphere</i> , 2017, 2, .	2.9	66
29	Investments in Research and Surveillance Are Needed to Go Beyond Elimination and Stop Transmission of <i>Leishmania</i> in the Indian Subcontinent. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005190.	3.0	26
30	Towards elimination of visceral leishmaniasis in the Indian subcontinent – Translating research to practice to public health. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005889.	3.0	53
31	Transmission Dynamics of Visceral Leishmaniasis in the Indian Subcontinent – A Systematic Literature Review. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004896.	3.0	74
32	Efficacy, Safety and Cost of Insecticide Treated Wall Lining, Insecticide Treated Bed Nets and Indoor Wall Wash with Lime for Visceral Leishmaniasis Vector Control in the Indian Sub-continent: A Multi-country Cluster Randomized Controlled Trial. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004932.	3.0	21
33	Longitudinal Study of Transmission in Households with Visceral Leishmaniasis, Asymptomatic Infections and PKDL in Highly Endemic Villages in Bihar, India. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0005196.	3.0	40
34	Repeated training of accredited social health activists (ASHAs) for improved detection of visceral leishmaniasis cases in Bihar, India. <i>Pathogens and Global Health</i> , 2016, 110, 33-35.	2.3	6
35	Entomological efficacy of durable wall lining with reduced wall surface coverage for strengthening visceral leishmaniasis vector control in Bangladesh, India and Nepal. <i>BMC Infectious Diseases</i> , 2016, 16, 539.	2.9	11
36	Mobile suitcase laboratory for rapid detection of <i>Leishmania donovani</i> using recombinase polymerase amplification assay. <i>Parasites and Vectors</i> , 2016, 9, 281.	2.5	98

#	ARTICLE	IF	CITATIONS
37	Adaptation of <i>Leishmania donovani</i> to Cutaneous and Visceral Environments: in Vivo Selection and Proteomic Analysis. <i>Journal of Proteome Research</i> , 2015, 14, 1033-1059.	3.7	20
38	Development of <i>Leishmania</i> vaccines in the era of visceral leishmaniasis elimination. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2015, 109, 423-424.	1.8	28
39	CRISPR-Cas9-Mediated Genome Editing in <i>Leishmania donovani</i> . <i>MBio</i> , 2015, 6, e00861.	4.1	168
40	Screening <i>Leishmania donovani</i> Complex-Specific Genes Required for Visceral Disease. <i>Methods in Molecular Biology</i> , 2015, 1201, 339-361.	0.9	4
41	Research priorities for elimination of visceral leishmaniasis. <i>The Lancet Global Health</i> , 2014, 2, e683-e684.	6.3	36
42	Asymptomatic <i>Leishmania</i> infections in northern India: a threat for the elimination programme?. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2014, 108, 679-684.	1.8	29
43	Genetic Analysis of <i>Leishmania donovani</i> Tropism Using a Naturally Attenuated Cutaneous Strain. <i>PLoS Pathogens</i> , 2014, 10, e1004244.	4.7	97
44	Impact of ASHA Training on Active Case Detection of Visceral Leishmaniasis in Bihar, India. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2774.	3.0	16
45	Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study. <i>The Lancet Global Health</i> , 2014, 2, e51-e57.	6.3	58
46	A2 and Other Visceralizing Proteins of <i>Leishmania</i> : Role in Pathogenesis and Application for Vaccine Development. <i>Sub-Cellular Biochemistry</i> , 2014, 74, 77-101.	2.4	11
47	Accelerated Active Case Detection of Visceral Leishmaniasis Patients in Endemic Villages of Bangladesh. <i>PLoS ONE</i> , 2014, 9, e103678.	2.5	5
48	Reducing Visceral Leishmaniasis by Insecticide Impregnation of Bed-Nets, Bangladesh. <i>Emerging Infectious Diseases</i> , 2013, 19, 1131-1134.	4.3	32
49	Determinants for the Development of Visceral Leishmaniasis Disease. <i>PLoS Pathogens</i> , 2013, 9, e1003053.	4.7	175
50	One More Death from Visceral Leishmaniasis Has Gone by Unnoticed. What Can Be Done?. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2082.	3.0	4
51	Diagnosis of Visceral Leishmaniasis in Bihar India: Comparison of the rK39 Rapid Diagnostic Test on Whole Blood Versus Serum. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2233.	3.0	25
52	A FRET-Based Real-Time PCR Assay to Identify the Main Causal Agents of New World Tegumentary Leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e1956.	3.0	31
53	Role of Cytosolic Glyceraldehyde-3-Phosphate Dehydrogenase in Visceral Organ Infection by <i>Leishmania donovani</i> . <i>Eukaryotic Cell</i> , 2013, 12, 70-77.	3.4	21
54	Cross-Sectional Study to Assess Risk Factors for Leishmaniasis in an Endemic Region in Sri Lanka. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 89, 742-749.	1.4	21

#	ARTICLE	IF	CITATIONS
55	Adjuvants for Leishmania vaccines: from models to clinical application. <i>Frontiers in Immunology</i> , 2012, 3, 144.	4.8	64
56	<i>Leishmania donovani</i> MON-37 isolated from an autochthonous visceral leishmaniasis patient in Sri Lanka. <i>Pathogens and Global Health</i> , 2012, 106, 421-424.	2.3	40
57	Involvement of the <i>Leishmania donovani</i> virulence factor A2 in protection against heat and oxidative stress. <i>Experimental Parasitology</i> , 2012, 132, 109-115.	1.2	29
58	Deletion of an ATP-binding cassette protein subfamily C transporter in <i>Leishmania donovani</i> results in increased virulence. <i>Molecular and Biochemical Parasitology</i> , 2012, 185, 165-169.	1.1	8
59	Generation and evaluation of A2-expressing <i>Lactococcus lactis</i> live vaccines against <i>Leishmania donovani</i> in BALB/c mice. <i>Journal of Medical Microbiology</i> , 2011, 60, 1248-1260.	1.8	28
60	Visceral leishmaniasis: elimination with existing interventions. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 322-325.	9.1	109
61	Intracellular Eukaryotic Parasites Have a Distinct Unfolded Protein Response. <i>PLoS ONE</i> , 2011, 6, e19118.	2.5	45
62	Expression of a <i>Leishmania donovani</i> nucleotide sugar transporter in <i>Leishmania major</i> enhances survival in visceral organs. <i>Experimental Parasitology</i> , 2011, 129, 337-345.	1.2	15
63	Localization and induction of the A2 virulence factor in <i>Leishmania</i> : evidence that A2 is a stress response protein. <i>Molecular Microbiology</i> , 2010, 77, 518-530.	2.5	60
64	Screening <i>Leishmania donovani</i> -specific genes required for visceral infection. <i>Molecular Microbiology</i> , 2010, 77, 505-517.	2.5	42
65	First-Line Therapy for Human Cutaneous Leishmaniasis in Peru Using the TLR7 Agonist Imiquimod in Combination with Pentavalent Antimony. <i>PLoS Neglected Tropical Diseases</i> , 2009, 3, e491.	3.0	65
66	Immunization with a Toll-Like Receptor 7 and/or 8 Agonist Vaccine Adjuvant Increases Protective Immunity against <i>Leishmania major</i> in BALB/c Mice. <i>Infection and Immunity</i> , 2008, 76, 3777-3783.	2.2	94
67	Comparison of the Effects of <i>Leishmania major</i> or <i>Leishmania donovani</i> Infection on Macrophage Gene Expression. <i>Infection and Immunity</i> , 2008, 76, 1186-1192.	2.2	81
68	A Genomic-Based Approach Combining In Vivo Selection in Mice to Identify a Novel Virulence Gene in <i>Leishmania</i> . <i>PLoS Neglected Tropical Diseases</i> , 2008, 2, e248.	3.0	25
69	Role of Imiquimod and Parenteral Meglumine Antimoniate in the Initial Treatment of Cutaneous Leishmaniasis. <i>Clinical Infectious Diseases</i> , 2007, 44, 1549-1554.	5.8	91
70	Viral load of episomal and integrated forms of human papillomavirus type 33 in high-grade squamous intraepithelial lesions of the uterine cervix. <i>International Journal of Cancer</i> , 2007, 121, 2674-2681.	5.1	14
71	Identification and Characterization of a Protein-tyrosine Phosphatase in <i>Leishmania</i> . <i>Journal of Biological Chemistry</i> , 2006, 281, 36257-36268.	3.4	39
72	Human Papillomavirus Type 33 Polymorphisms and High-Grade Squamous Intraepithelial Lesions of the Uterine Cervix. <i>Journal of Infectious Diseases</i> , 2006, 194, 886-894.	4.0	33

#	ARTICLE	IF	CITATIONS
73	Development of a Genetic Assay to Distinguish between <i>Leishmania viannia</i> Species on the Basis of Isoenzyme Differences. <i>Clinical Infectious Diseases</i> , 2006, 42, 801-809.	5.8	34
74	Involvement of Nuclear Export in Human Papillomavirus Type 18 E6-Mediated Ubiquitination and Degradation of p53. <i>Journal of Virology</i> , 2005, 79, 8773-8783.	3.4	33
75	Regulation of Human p53 Activity and Cell Localization by Alternative Splicing. <i>Molecular and Cellular Biology</i> , 2004, 24, 7987-7997.	2.3	197
76	Control of $\hat{\pm}$ Subunit of Eukaryotic Translation Initiation Factor 2 (eIF2 $\hat{\pm}$) Phosphorylation by the Human Papillomavirus Type 18 E6 Oncoprotein: Implications for eIF2 $\hat{\pm}$ -Dependent Gene Expression and Cell Death. <i>Molecular and Cellular Biology</i> , 2004, 24, 3415-3429.	2.3	93
77	In vivo selection for <i>Leishmania donovani</i> miniexon genes that increase virulence in <i>Leishmania major</i> . <i>Molecular Microbiology</i> , 2004, 54, 1051-1062.	2.5	14
78	Ubiquitination and proteasome degradation of the E6 proteins of human papillomavirus types 11 and 18. <i>Journal of General Virology</i> , 2004, 85, 1419-1426.	2.9	27
79	Heterologous expression of a mammalian protein tyrosine phosphatase gene in <i>Leishmania</i> : effect on differentiation. <i>Molecular Microbiology</i> , 2003, 50, 1517-1526.	2.5	16
80	Comparison of the A2 Gene Locus in <i>Leishmania donovani</i> and <i>Leishmania major</i> and Its Control over Cutaneous Infection. <i>Journal of Biological Chemistry</i> , 2003, 278, 35508-35515.	3.4	99
81	Immune Responses Induced by the <i>Leishmania (Leishmania) donovani</i> A2 Antigen, but Not by the LACK Antigen, Are Protective against Experimental <i>Leishmania (Leishmania) amazonensis</i> Infection. <i>Infection and Immunity</i> , 2003, 71, 3988-3994.	2.2	220
82	Diagnosis of American visceral leishmaniasis in humans and dogs using the recombinant <i>Leishmania donovani</i> A2 antigen. <i>Diagnostic Microbiology and Infectious Disease</i> , 2002, 43, 289-295.	1.8	86
83	Detection of iNOS gene expression in cutaneous leishmaniasis biopsy tissue. <i>Molecular and Biochemical Parasitology</i> , 2002, 121, 145-147.	1.1	9
84	Successful Treatment of Drug-Resistant Cutaneous Leishmaniasis in Humans by Use of Imiquimod, an Immunomodulator. <i>Clinical Infectious Diseases</i> , 2001, 33, 1847-1851.	5.8	158
85	<i>Leishmania</i> infection and virulence. <i>Medical Microbiology and Immunology</i> , 2001, 190, 37-42.	4.8	66
86	Characterization of the A2-A2rel gene cluster in <i>Leishmania donovani</i> : involvement of A2 in visceralization during infection. <i>Molecular Microbiology</i> , 2001, 39, 935-948.	2.5	111
87	Identification of Genes Induced by a Macrophage Activator, S-28463, Using Gene Expression Array Analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1137-1142.	3.2	35
88	Clearance of Infection with <i>Mycobacterium bovis</i> BCG in Mice Is Enhanced by Treatment with S28463 (R-848), and Its Efficiency Depends on Expression of Wild-Type Nrp1 (Resistance Allele). <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 3059-3064.	3.2	17
89	General Suppression of Macrophage Gene Expression During <i>Leishmania donovani</i> Infection. <i>Journal of Immunology</i> , 2001, 166, 3416-3422.	0.8	120
90	Analysis of antisense and double stranded RNA downregulation of A2 protein expression in <i>Leishmania donovani</i> . <i>Molecular and Biochemical Parasitology</i> , 2000, 107, 315-319.	1.1	25

#	ARTICLE	IF	CITATIONS
91	Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically. <i>Molecular and Cellular Biology</i> , 1999, 19, 1092-1100.	2.3	633
92	Treatment of Experimental Leishmaniasis with the Immunomodulators Imiquimod and Sâ€28463: Efficacy and Mode of Action. <i>Journal of Infectious Diseases</i> , 1999, 179, 1485-1494.	4.0	148
93	p53: Twenty years on, Meeting Review. <i>Oncogene</i> , 1999, 18, 7618-7620.	5.9	8
94	Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 1999, 6, 223-233.	1.1	80
95	Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer. <i>Nature</i> , 1998, 393, 229-234.	27.8	897
96	p53 polymorphism and risk of cervical cancer. <i>Nature</i> , 1998, 396, 532-532.	27.8	9
97	A2rel: a constitutively expressed Leishmania gene linked to an amastigote-stage-specific gene1Note: The sequence is also available on GenBankâ„, accession number AF016403.1. <i>Molecular and Biochemical Parasitology</i> , 1998, 93, 23-29.	1.1	15
98	Inducible Expression of Suicide Genes in Leishmania donovani Amastigotes. <i>Journal of Biological Chemistry</i> , 1998, 273, 22997-23003.	3.4	29
99	Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani. <i>Molecular and Biochemical Parasitology</i> , 1996, 78, 79-90.	1.1	130
100	The Developmental Expression of A2 Amastigote-specific Genes Is Post-transcriptionally Mediated and Involves Elements Located in the 3â€-Untranslated Region. <i>Journal of Biological Chemistry</i> , 1996, 271, 17081-17090.	3.4	120
101	The expression of biologically active human p53 inLeishmaniacells: a novel eukaryotic system to produce recombinant proteins. <i>Nucleic Acids Research</i> , 1995, 23, 4073-4080.	14.5	47
102	<i>Leishmania donovani</i> infection enhances macrophage viability in the absence of exogenous growth factor. <i>Journal of Leukocyte Biology</i> , 1994, 55, 91-98.	3.3	24
103	Molecular analysis of different allelic variants of wild-type human p53. <i>Biochemistry and Cell Biology</i> , 1992, 70, 1014-1019.	2.0	10
104	Identification of a novel Brugia pahangi Î²-tubulin gene (Î²2) and a 22-nucleotide spliced leader sequence on Î²1-tubulin mRNA. <i>Molecular and Biochemical Parasitology</i> , 1992, 50, 275-284.	1.1	16
105	Characterization of a Î²-tubulin gene and Î²-tubulin gene products of Brugia pahangi. <i>Molecular and Biochemical Parasitology</i> , 1991, 44, 153-164.	1.1	31
106	Transformation of primary human fibroblast cells with human papillomavirus type 16 DNA and Ej-ras. <i>International Journal of Cancer</i> , 1988, 42, 232-238.	5.1	41
107	Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. <i>FEBS Journal</i> , 1986, 159, 529-534.	0.2	469
108	Analysis of human p53 proteins and mRNA levels in normal and transformed cells. <i>FEBS Journal</i> , 1986, 154, 665-672.	0.2	136

#	ARTICLE	IF	CITATIONS
109	The use of monoclonal antibodies for selection of a low-abundance mRNA: p53. Biochemical Society Transactions, 1984, 12, 708-711.	3.4	1